# EDGAR Filing Document

**Accession Number:** 0001850119
**File Stem:** 0001104659-26-073429
**Filing Date:** 2026-6
**Character Count:** 11931
**Document Hash:** a4d367544c387c2ab0b79701740361a4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-073429.hdr.sgml**: 20260612

**ACCESSION NUMBER**: 0001104659-26-073429

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260611

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260612

**DATE AS OF CHANGE**: 20260612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Century Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001850119
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 842040295
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40498
- **FILM NUMBER:** 261086619

**BUSINESS ADDRESS:**
- **STREET 1:** 25 N 38TH STREET, 11TH FLOOR
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19104
- **BUSINESS PHONE:** 215-981-4000

**MAIL ADDRESS:**
- **STREET 1:** 25 N 38TH STREET, 11TH FLOOR
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19104

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 11, 2026**

**Century Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40498** | **84-2040295** |
| (State or other jurisdiction of<br> incorporation or organization) | (Commission File Number) | (I.R.S. Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **25 North 38th Street**, **11th Floor**<br> **Philadelphia, Pennsylvania**  | **19104** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(267) 817-5790**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

---

| |
|:---|
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol** | **Name of Exchange on Which Registered** |
| **Common Stock, par value $0.0001 per share** | **IPSC** | **Nasdaq Capital Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 5.03** | **<u>Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.</u>** |

---

As further described under Item 5.07 of this Current Report on this Form 8-K, at the 2026 Annual Meeting of Stockholders (the "Annual Meeting"), and upon the recommendation of the Board of Directors (the "Board"), the stockholders of Century Therapeutics, Inc. (the "Company") approved a Certificate of Amendment to the Company's Second Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock, par value $0.0001 per share ("Common Stock", and such amendment, the "Authorized Shares Amendment"). The Authorized Shares Amendment was previously approved by the Board, subject to stockholder approval.

The Authorized Shares Amendment was filed with the Secretary of State of the State of Delaware on June 11, 2026. The Authorized Shares Amendment became effective on June 12, 2026.

The foregoing description of the Authorized Shares Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is filed as Exhibit 3.1 to this Form 8-K and incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 5.07** | **<u>Submission of Matters to a Vote of Security Holders.</u>** |

---

On June 11, 2026, the Company held its Annual Meeting. As of April 16, 2026, the record date for the Annual Meeting, there were 180,354,197 outstanding shares of the Company's common stock. The Annual Meeting was conducted virtually, and the following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the Annual Meeting, which are described in detail in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities Exchange Commission on April 27, 2026.

(a) *Proposal 1 - Election of Class II Directors*. Each of Alessandro Riva, M.D. and Han Lee, Ph.D., M.B.A., were elected to the Company's Board to serve as Class II directors until the 2029 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or their earlier death, resignation, retirement, disqualification or removal, as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Name** | **For** | **For** | **Withheld** | **Withheld** | **Broker Non-Votes** | **Broker Non-Votes** |
| Alessandro Riva, M.D. |  | 96165182 |  | 17582584 |  | 21941333 |
| Han Lee, Ph.D., M.B.A. |  | 113675805 |  | 71961 |  | 21941333 |

---

(b) *Proposal 2 - Ratification of Independent Registered Public Accountant*. The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the 2026 fiscal year was ratified, as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **For** | **For** | **Against** | **Against** | **Abstentions** | **Abstentions** | **Broker Non-Votes** | **Broker Non-Votes** |
|  | 135560408 |  | 107111 |  | 21578 |  | 0 |

---

(c) *Proposal 3 - Approval of an amendment to the Second Amended and Restated Certificate of Incorporation, as amended.* The amendment to the Company's Second Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 300,000,000 to 450,000,000 was approved, as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **For** | **For** | **Against** | **Against** | **Abstentions** | **Abstentions** | **Broker Non-Votes** | **Broker Non-Votes** |
|  | 117444445 |  | 18150386 |  | 94262 |  | 0 |

---

(d) *Proposal 4 - Approval of an adjournment of the Annual Meeting.* The adjournment of the Annual Meeting to the extent there were insufficient votes to approve Proposal 3 was approved, but such an adjournment was not necessary in light of the approval of Proposal 3 at the Annual Meeting. The adjournment was approved, as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **For** | **For** | **Against** | **Against** | **Abstentions** | **Abstentions** | **Broker Non-Votes** | **Broker Non-Votes** |
|  | 117181181 |  | 18419826 |  | 88087 |  | 0 |

---

---

| | |
|:---|:---|
| **Item 9.01** | **<u>Financial Statements and Exhibits.</u>** |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit<br> No.** | **Document** |
| [3.1](tm2617728d1_ex3-1.htm) | [Certificate of Amendment of the Second Amended and Restated Certificate of Incorporation, as amended, of Century Therapeutics, Inc.](tm2617728d1_ex3-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **CENTURY THERAPEUTICS, INC.** | **CENTURY THERAPEUTICS, INC.** |
| By: | /s/ Brent Pfeiffenberger, Pharm.D. |
| Name: | Brent Pfeiffenberger, Pharm.D. |
| Title: | President, Chief Executive Officer and Chairman of the Board of Directors |

---

Date: June 12, 2026

## Exhibit 3.1

**Exhibit 3.1**

**CERTIFICATE OF AMENDMENT**

**TO THE**

**CERTIFICATE OF INCORPORATION OF**

**CENTURY THERAPEUTICS, INC.**

Century Therapeutics, Inc. (the "<u>Corporation</u>"), a corporation organized and existing under the provisions of the General Corporation Law of the State of Delaware (the "<u>DGCL</u>"), hereby certifies that:

1. The name of this corporation is Century Therapeutics, Inc. The Corporation's original Certificate
of Incorporation was filed with the Secretary of State of the State of Delaware on February 25, 2021. Pursuant to Section 242
of the DGCL, this Certificate of Amendment (this " <u>Amendment</u> ") amends certain provisions of the Company's Second
Amended and Restated Certificate of Incorporation, as amended (the " <u>Charter</u> ").

2. This Amendment has been approved and duly adopted by the Corporation's Board of Directors and stockholders
in accordance with the provisions of Section 242 of the DGCL.

3. Article IV of the Charter is hereby amended and restated in its entirety as follows:

Article IV

<u>Capital Stock</u>

The total number of shares of capital stock which the Corporation shall have authority to issue is 460,000,000 of which (i) 450,000,000 shares shall be a class designated as common stock, par value $0.0001 per share (the "<u>Common Stock</u>"), and (ii) 10,000,000 shares shall be a class designated as undesignated preferred stock, par value $0.0001 per share (the "<u>Undesignated Preferred Stock</u>").

Except as otherwise provided in any certificate of designations of any series of Undesignated Preferred Stock, the number of authorized shares of the class of Common Stock or Undesignated Preferred Stock may from time to time be increased or decreased (but not below the number of shares of such class outstanding) by the affirmative vote of the holders of a majority in voting power of the outstanding shares of capital stock of the Corporation irrespective of the provisions of Section 242(b)(2) of the DGCL.

The powers, preferences and rights of, and the qualifications, limitations and restrictions upon, each class or series of stock shall be determined in accordance with, or as set forth below in, this Article IV.

4. This Amendment shall become effective on June 12<sup>th</sup>, 2026 at 12:01 a.m. Eastern Time.

5. Except as set forth in this Amendment, the Charter remains in full force and effect.

[*Remainder of Page Intentionally Left Blank*]

IN WITNESS WHEREOF, this Certificate of Amendment to the Certificate of Incorporation has been executed by a duly authorized officer of this Corporation on this 11<sup>th</sup> day of June, 2026.

---

| | |
|:---|:---|
| CENTURY THERAPEUTICS, INC. | CENTURY THERAPEUTICS, INC. |
| By: | /s/ Brent Pfeiffenberger, Pharm.D. |
| Brent Pfeiffenberger, Pharm.D. | Brent Pfeiffenberger, Pharm.D. |
| President, Chief Executive Officer and Chairman of the Board of Directors | President, Chief Executive Officer and Chairman of the Board of Directors |

---